AR073314A1 - Derivados de indazol o de 4,5,6,7-tetrahidro-indazol - Google Patents
Derivados de indazol o de 4,5,6,7-tetrahidro-indazolInfo
- Publication number
- AR073314A1 AR073314A1 ARP090103661A ARP090103661A AR073314A1 AR 073314 A1 AR073314 A1 AR 073314A1 AR P090103661 A ARP090103661 A AR P090103661A AR P090103661 A ARP090103661 A AR P090103661A AR 073314 A1 AR073314 A1 AR 073314A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- alkoxy
- alkyl
- hydroxy
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 16
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- 125000001188 haloalkyl group Chemical group 0.000 abstract 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 9
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 7
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 abstract 5
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 5
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 hydroxy, carboxyl Chemical group 0.000 abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 1
- LSYICPNAJSMBIC-UHFFFAOYSA-N hydroxymethyl hypofluorite Chemical compound OCOF LSYICPNAJSMBIC-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos son moduladores de FXR y pueden utilizarse como medicamentos. Reivindicacion 1: Compuestos de la formula (1) en la que R1 es un anillo elegido entre el grupo formado por fenilo, naftilo y heteroarilo, dicho anillo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano; R2, R3, R4 y R5 con independencia entre sí se eligen entre el grupo formado por H, halogeno y alquilo inferior; R2' y R3' juntos y también R4' y R5' juntos se reemplazan por un doble enlace, o R2', R3', R4' y R5' son H; R6 se elige entre el grupo formado por H, metilo, etilo, hidroxi, metoxi, fluor, fluormetilo, difluormetilo y trifluormetilo; R7 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, alcoxialquilo inferior, fenilo sin sustituir o fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano; fenilalquilo inferior, en el que el fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano; heteroarilo sin sustituir o heteroarilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano; y heterociclilo; y R8 se elige entre el grupo formado por -C(O)-NH-R9, -CR11R12-OR10, -O-(CR11R12)n-R10; -CR11R12-SR10, -CR11R12-SO2-R10, -CR11R12-NR13-R10; -CH=CH-R10 y -(CH2)p-R10, en los que n es el numero 0 o 1, p es el numero 2, R9 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, cicloalquilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por hidroxi, carboxilo, tetrazolilo, carboxialquilo inferior, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalcoxi inferior y alcoxicarbonilalcoxi inferior, heterociclilo, fenilo sin sustituir y fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)carbonilo, alcoxicarbonilalquilo inferior, carboxialquilo inferior, carboxialcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, en los que el grupo cicloalquilo esta sustituido por carboxilo, (alcoxi inferior)-carbonilo o tetrazolilo; R10 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, cicloalquilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por hidroxi, carboxilo, tetrazolilo, carboxialquilo inferior, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalcoxi inferior y alcoxicarbonilalcoxi inferior, heterociclilo, piridilo sin sustituir y piridilo sustituido por carboxilo, (alcoxi inferior)-carbonilo o tetrazolilo, fenilo sin sustituir y fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)carbonilo, alcoxicarbonilalquilo inferior, carboxialquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, en los que el grupo cicloalquilo esta sustituido por carboxilo, (alcoxi inferior)-carbonilo o tetrazolilo; fenilalquilo inferior, en el que el fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)carbonilo, alcoxicarbonilalquilo inferior, carboxialquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, en los que el grupo cicloalquilo esta sustituido por carboxilo, (alcoxi inferior)-carbonilo o tetrazolilo; R11 y R12 se eligen con independencia entre el grupo formado por H, alquilo inferior y halogenoalquilo inferior, o R11 y R12 junto con el átomo de C al que están unidos forman un anillo cicloalquilo o alcoxicicloalquilo; y R13 se elige entre el grupo formado por H, alquilo inferior y halogenoalquilo inferior; o las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08165145 | 2008-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073314A1 true AR073314A1 (es) | 2010-10-28 |
Family
ID=41397504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103661A AR073314A1 (es) | 2008-09-25 | 2009-09-23 | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8008505B2 (es) |
| EP (1) | EP2344459B1 (es) |
| JP (1) | JP5425911B2 (es) |
| KR (1) | KR101372104B1 (es) |
| CN (1) | CN102164899B (es) |
| AR (1) | AR073314A1 (es) |
| AU (1) | AU2009296048A1 (es) |
| BR (1) | BRPI0919057A2 (es) |
| CA (1) | CA2735886A1 (es) |
| ES (1) | ES2446593T3 (es) |
| IL (1) | IL211566A0 (es) |
| MX (1) | MX2011002794A (es) |
| TW (1) | TW201020235A (es) |
| WO (1) | WO2010034649A1 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010279575B2 (en) | 2009-08-03 | 2016-05-05 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| US8721620B2 (en) | 2009-12-24 | 2014-05-13 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
| US8252826B2 (en) | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| AU2012213086B2 (en) | 2011-02-03 | 2016-05-05 | Lupin Limited | Pyrrole derivatives used as modulators of alpha7 nAChR |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| PL3043865T3 (pl) | 2013-09-11 | 2021-07-05 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B |
| CN110117273B (zh) * | 2014-07-24 | 2022-02-01 | 贝达医药公司 | 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途 |
| US20190031667A1 (en) | 2016-02-05 | 2019-01-31 | Syngenta Participations Ag | Pesticidally active heterocyclic derivatives with sulphur containing substituents |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| JP6678779B2 (ja) | 2016-06-13 | 2020-04-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒ（ｎｒ１ｈ４）調節化合物 |
| WO2018153933A1 (en) | 2017-02-21 | 2018-08-30 | Genfit | Combination of a ppar agonist with a fxr agonist |
| EP4122464B1 (en) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
| EP3600293A1 (en) | 2017-03-30 | 2020-02-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| KR200484938Y1 (ko) | 2017-06-08 | 2017-11-08 | 한지영 | 머리카락 선별 커팅기구 |
| EP3911647B1 (en) | 2019-01-15 | 2023-12-13 | Gilead Sciences, Inc. | Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same |
| AU2020225225B2 (en) | 2019-02-19 | 2022-12-22 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
| JP2022523430A (ja) | 2019-03-08 | 2022-04-22 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 硫黄含有置換基を有する殺有害生物的に活性な複素環式誘導体 |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| WO2021136722A1 (en) | 2019-12-31 | 2021-07-08 | Syngenta Crop Protection Ag | Pesticidally active heterocyclic derivatives with sulfur containing substituents |
| CN114945361A (zh) | 2020-01-15 | 2022-08-26 | 法国国家卫生及研究医学协会 | Fxr激动剂在治疗丁型肝炎病毒感染中的用途 |
| WO2021213929A1 (en) | 2020-04-20 | 2021-10-28 | Syngenta Crop Protection Ag | Pesticidally active substituted 1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives with sulfur containing substituents |
| WO2021224409A1 (en) | 2020-05-06 | 2021-11-11 | Syngenta Crop Protection Ag | Pesticidally active heterocyclic derivatives with sulfur containing substituents |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| US20240100125A1 (en) | 2021-01-14 | 2024-03-28 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| WO2022157334A1 (en) | 2021-01-21 | 2022-07-28 | Syngenta Crop Protection Ag | Pesticidally active heterocyclic derivatives with sulfur containing substituents |
| EP4329761A1 (en) | 2021-04-28 | 2024-03-06 | ENYO Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| CN116332851A (zh) * | 2023-03-09 | 2023-06-27 | 河南中医药大学 | 一种氰甲基苯基吲唑类化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5134155A (en) * | 1991-08-08 | 1992-07-28 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors |
| CA2561305C (en) * | 2004-03-24 | 2013-07-30 | Bharat Lagu | Tetrahydro-indazole cannabinoid modulators |
| US8378096B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| ITMI20051989A1 (it) * | 2005-10-20 | 2007-04-21 | Dipharma Spa | Procedimerntyo per la preparazione di composti antagonisti di angiotensina ii |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| AR061101A1 (es) | 2006-05-24 | 2008-08-06 | Lilly Co Eli | Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende |
| AU2009295967A1 (en) * | 2008-09-25 | 2010-04-01 | F. Hoffmann-La Roche Ag | 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives |
-
2009
- 2009-09-15 CN CN200980137812.8A patent/CN102164899B/zh not_active Expired - Fee Related
- 2009-09-15 MX MX2011002794A patent/MX2011002794A/es active IP Right Grant
- 2009-09-15 BR BRPI0919057A patent/BRPI0919057A2/pt not_active IP Right Cessation
- 2009-09-15 ES ES09783005.3T patent/ES2446593T3/es active Active
- 2009-09-15 AU AU2009296048A patent/AU2009296048A1/en not_active Abandoned
- 2009-09-15 JP JP2011528289A patent/JP5425911B2/ja not_active Expired - Fee Related
- 2009-09-15 EP EP09783005.3A patent/EP2344459B1/en not_active Not-in-force
- 2009-09-15 CA CA2735886A patent/CA2735886A1/en not_active Abandoned
- 2009-09-15 KR KR1020117009279A patent/KR101372104B1/ko not_active Expired - Fee Related
- 2009-09-15 WO PCT/EP2009/061912 patent/WO2010034649A1/en not_active Ceased
- 2009-09-21 US US12/563,193 patent/US8008505B2/en not_active Expired - Fee Related
- 2009-09-22 TW TW098131983A patent/TW201020235A/zh unknown
- 2009-09-23 AR ARP090103661A patent/AR073314A1/es unknown
-
2011
- 2011-03-03 IL IL211566A patent/IL211566A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009296048A1 (en) | 2010-04-01 |
| US20100076027A1 (en) | 2010-03-25 |
| IL211566A0 (en) | 2011-05-31 |
| KR20110059895A (ko) | 2011-06-07 |
| JP5425911B2 (ja) | 2014-02-26 |
| JP2012503617A (ja) | 2012-02-09 |
| ES2446593T3 (es) | 2014-03-10 |
| EP2344459A1 (en) | 2011-07-20 |
| CA2735886A1 (en) | 2010-04-01 |
| MX2011002794A (es) | 2011-04-05 |
| US8008505B2 (en) | 2011-08-30 |
| CN102164899A (zh) | 2011-08-24 |
| WO2010034649A1 (en) | 2010-04-01 |
| BRPI0919057A2 (pt) | 2018-01-09 |
| TW201020235A (en) | 2010-06-01 |
| KR101372104B1 (ko) | 2014-03-07 |
| CN102164899B (zh) | 2014-11-26 |
| EP2344459B1 (en) | 2013-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| AR073396A1 (es) | Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| PE20171057A1 (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| BR112015032637A2 (pt) | derivados de pirrolopiridina ou pirazolopiridina | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| AR061815A1 (es) | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| PE20211240A1 (es) | Inhibidores de endonucleasa cap-dependientes | |
| AR078622A1 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
| JP2013509392A5 (es) | ||
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| AR072809A1 (es) | Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| MX2018014944A (es) | Tratamiento para la enfermedad de parkinson. | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| AR059018A1 (es) | Derivados de 6- fenil -1h- imidazo (4,5-c) piridina -4- carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina s y/o catepsina k |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |